Pine Valley Investments Ltd Liability Co Has $9.20 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Pine Valley Investments Ltd Liability Co lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,676 shares of the medical research company’s stock after purchasing an additional 769 shares during the period. Pine Valley Investments Ltd Liability Co’s holdings in Thermo Fisher Scientific were worth $9,197,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the business. BankPlus Trust Department bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $1,300,000. Edge Capital Group LLC raised its stake in shares of Thermo Fisher Scientific by 7.4% during the fourth quarter. Edge Capital Group LLC now owns 2,862 shares of the medical research company’s stock worth $1,489,000 after buying an additional 197 shares during the last quarter. IFP Advisors Inc raised its stake in shares of Thermo Fisher Scientific by 18.6% during the fourth quarter. IFP Advisors Inc now owns 7,508 shares of the medical research company’s stock worth $3,907,000 after buying an additional 1,178 shares during the last quarter. Rowlandmiller & PARTNERS.ADV raised its stake in shares of Thermo Fisher Scientific by 12.8% during the fourth quarter. Rowlandmiller & PARTNERS.ADV now owns 264 shares of the medical research company’s stock worth $137,000 after buying an additional 30 shares during the last quarter. Finally, Waverton Investment Management Ltd raised its stake in shares of Thermo Fisher Scientific by 13.0% during the fourth quarter. Waverton Investment Management Ltd now owns 542,405 shares of the medical research company’s stock worth $282,186,000 after buying an additional 62,189 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $535.55 on Tuesday. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88. The firm has a fifty day simple moving average of $548.58 and a 200 day simple moving average of $566.86. The stock has a market capitalization of $204.85 billion, a price-to-earnings ratio of 32.40, a PEG ratio of 2.99 and a beta of 0.77. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.32%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.41%.

Thermo Fisher Scientific announced that its board has initiated a share repurchase program on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

TMO has been the subject of several recent analyst reports. Bank of America lowered their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research note on Friday, December 13th. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Raymond James reaffirmed an “outperform” rating and issued a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a research note on Friday, January 10th. Finally, UBS Group upped their target price on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $656.86.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the sale, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the sale, the chief financial officer now owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 20,125 shares of company stock worth $11,231,699 over the last quarter. 0.34% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.